{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "M",
          "alt": "I",
          "position": "26"
        },
        "variant_string_id": "DJ-1 M26I"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Loss-of-function mutations in the DJ-1 gene (PARK7) cause autosomal-recessive hereditary Parkinson disease (PD). The cytoprotective activity of DJ-1 against oxidative stress depends on its cysteine residues, particularly Cys-106, and is impaired in PD-associated mutations like M26I.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as loss-of-function in DJ-1 leading to reduced cytoprotection against oxidative stress, which is central to PD pathogenesis and relevant to the functional assays described for M26I."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Functional assays included ASK1 binding and suppression assays, cytotoxicity (LDH release) assays, and Daxx translocation assays in DJ-1 knockout MEF cells to assess cytoprotective activity under oxidative stress.",
          "judgment": "Yes",
          "reasoning": "These assays (ASK1 binding/suppression, cytotoxicity, and Daxx translocation) are relevant and widely used in the field to model PD pathogenesis through oxidative stress response and apoptosis pathways, directly reflecting the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Experiments used DJ-1 knockout MEF cells as a null background, wild-type DJ-1 as a positive control, and vector controls as negative controls. Assays were performed with replicates (e.g., 'results are representative of two or three independent experiments' and 'mean values Â± S.E. of 2-4 independent experiments').",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type DJ-1) and abnormal (vector control in knockout cells) controls were included, and the paper explicitly mentions multiple independent experiments, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study tested multiple DJ-1 variants, including known loss-of-function mutant L166P (pathogenic) and other cysteine mutants like C106A (loss-of-function) as controls alongside M26I. L166P is a well-established pathogenic variant in PD.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant controls (e.g., L166P) were used in the assays, meeting the criteria for variant controls without relying on PS3/BS3 evidence for their classification.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis was performed using analysis of variance with Bonferroni multiple comparisons post-test. Specific p-values are reported for cytotoxicity (e.g., p < 0.05, p < 0.001) and Daxx translocation (p < 0.02), but no direct OddsPath calculation is provided.",
          "judgment": "No",
          "reasoning": "While statistical tests and p-values are reported, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood from the functional data for M26I, necessitating further evaluation under Step 4b.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes multiple variant controls: L166P (pathogenic), C106A (pathogenic), C46A, C53A, C106DD, C106EE (varied effects), totaling more than 11 variants tested across assays relevant to M26I.",
          "judgment": "At least 11",
          "reasoning": "The total number of benign and pathogenic variant controls used across the study exceeds 10, meeting the threshold for moderate evidence strength in the absence of OddsPath calculation.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for DJ-1 M26I supports a pathogenic role with moderate strength (PS3_moderate) due to demonstrated loss of cytoprotective activity, failure to suppress ASK1 activity, and inability to prevent Daxx nuclear export in relevant assays. The assessment progressed through all steps with sufficient controls, replicates, and variant controls, and despite lacking OddsPath, the large number of variant controls justifies the moderate strength rating."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "C",
          "alt": "A",
          "position": "106"
        },
        "variant_string_id": "DJ-1 C106A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Loss-of-function mutations in DJ-1 cause PD by impairing cytoprotection against oxidative stress, with Cys-106 being critical for DJ-1's redox-dependent activity and binding to ASK1.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as loss-of-function in DJ-1 leading to reduced cytoprotection against oxidative stress, directly relevant to the functional assays for C106A."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Functional assays included ASK1 binding and suppression assays, cytotoxicity (LDH release) assays in DJ-1 knockout MEF cells to assess cytoprotective activity under oxidative stress.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant and standard in the field for modeling PD pathogenesis through oxidative stress response and apoptosis pathways, reflecting the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Experiments used DJ-1 knockout MEF cells as a null background, wild-type DJ-1 as a positive control, and vector controls as negative controls. Assays were performed with replicates (e.g., 'results are representative of two or three independent experiments').",
          "judgment": "Yes",
          "reasoning": "Both normal and abnormal controls were included, and multiple independent experiments are mentioned, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study tested multiple DJ-1 variants, including known loss-of-function mutant L166P (pathogenic) and other mutants like M26I alongside C106A. L166P is a well-established pathogenic variant in PD.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant controls (e.g., L166P) were used, meeting the criteria for variant controls without relying on PS3/BS3 evidence for their classification.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis was performed with p-values reported for cytotoxicity (e.g., p < 0.001), but no direct OddsPath calculation is provided for C106A.",
          "judgment": "No",
          "reasoning": "While statistical significance is reported, there is no direct OddsPath calculation or estimation for pathogenicity likelihood from functional data for C106A, requiring evaluation under Step 4b.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes multiple variant controls: L166P, M26I, C46A, C53A, C106DD, C106EE, totaling more than 11 variants tested across relevant assays.",
          "judgment": "At least 11",
          "reasoning": "The total number of benign and pathogenic variant controls exceeds 10, meeting the threshold for moderate evidence strength in the absence of OddsPath.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for DJ-1 C106A supports a pathogenic role with moderate strength (PS3_moderate) due to complete loss of cytoprotective activity and failure to bind or suppress ASK1 under oxidative stress. The assessment confirms sufficient controls, replicates, and variant controls, and the large number of variant controls justifies the moderate strength rating despite lacking OddsPath."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "C",
          "alt": "A",
          "position": "46"
        },
        "variant_string_id": "DJ-1 C46A"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Loss-of-function mutations in DJ-1 cause PD by impairing cytoprotection against oxidative stress, with cysteine residues playing roles in DJ-1 activity.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined as loss-of-function in DJ-1 leading to reduced cytoprotection, relevant to the functional assays for C46A."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Functional assays included ASK1 binding assays and cytotoxicity (LDH release) assays in DJ-1 knockout MEF cells to assess cytoprotective activity.",
          "judgment": "Yes",
          "reasoning": "These assays are standard and relevant for modeling PD pathogenesis through oxidative stress response, reflecting the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Experiments used DJ-1 knockout MEF cells as a null background, wild-type DJ-1 as a positive control, and vector controls as negative controls, with replicates mentioned (e.g., 'two or three independent experiments').",
          "judgment": "Yes",
          "reasoning": "Both normal and abnormal controls were included, and multiple independent experiments are mentioned, satisfying the criteria.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study tested multiple DJ-1 variants, including known pathogenic L166P and other mutants like M26I and C106A alongside C46A.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant controls (e.g., L166P) were used, meeting the criteria for variant controls without relying on PS3/BS3 evidence.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis with p-values reported for cytotoxicity (e.g., p < 0.05), but no direct OddsPath calculation for C46A.",
          "judgment": "No",
          "reasoning": "No direct OddsPath calculation or estimation for pathogenicity likelihood is provided, requiring evaluation under Step 4b.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes multiple variant controls (L166P, M26I, C106A, C53A, C106DD, etc.), totaling more than 11 variants tested.",
          "judgment": "At least 11",
          "reasoning": "The total number of variant controls exceeds 10, meeting the threshold for moderate evidence strength in the absence of OddsPath.",
          "next_step_or_outcome": "Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "The functional evidence for DJ-1 C46A supports a benign role with moderate strength (BS3_moderate) due to retained cytoprotective activity and constitutive ASK1 binding despite reduced protein stability. The assessment confirms sufficient controls and replicates, and the large number of variant controls justifies the moderate strength rating."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "C",
          "alt": "A",
          "position": "53"
        },
        "variant_string_id": "DJ-1 C53A"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Loss-of-function mutations in DJ-1 cause PD by impairing cytoprotection against oxidative stress, with cysteine residues modulating DJ-1 activity.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined and relevant to the functional assays for C53A."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Functional assays included ASK1 binding and suppression assays, cytotoxicity (LDH release) assays in DJ-1 knockout MEF cells.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant for modeling PD pathogenesis through oxidative stress response.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Experiments used DJ-1 knockout MEF cells, wild-type DJ-1, and vector controls, with replicates mentioned (e.g., 'two or three independent experiments').",
          "judgment": "Yes",
          "reasoning": "Both controls and replicates are satisfied as per the paper's descriptions.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Multiple DJ-1 variants tested, including known pathogenic L166P alongside C53A.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant controls were used, meeting the criteria.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis with p-values reported, but no direct OddsPath calculation for C53A.",
          "judgment": "No",
          "reasoning": "No OddsPath calculation provided, requiring evaluation under Step 4b.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "More than 11 variant controls tested across assays (L166P, M26I, C106A, C46A, etc.).",
          "judgment": "At least 11",
          "reasoning": "The threshold for moderate evidence strength is met with over 10 variant controls.",
          "next_step_or_outcome": "Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "The functional evidence for DJ-1 C53A supports a benign role with moderate strength (BS3_moderate) due to retained cytoprotective activity and strong suppression of ASK1 kinase activity. The large number of variant controls justifies the moderate strength rating."
    }
  ]
}